Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1100-1108. doi: 10.1016/j.ijrobp.2018.11.045. Epub 2018 Nov 30.
Multibeam intensity modulated radiation therapy (IMRT) enhances the therapeutic index by increasing the dosimetric coverage of the targeted tumor tissues while minimizing volumes of adjacent organs receiving high doses of RT. The tradeoff is that a greater volume of lung is exposed to low doses of RT, raising concern about the risk of radiation pneumonitis (RP).
Between July 2010 and January 2013, patients with node-positive breast cancer received inverse-planned, multibeam IMRT to the breast or chest wall and regional nodes, including the internal mammary nodes (IMNs). The primary endpoint was feasibility, predefined by dosimetric treatment planning criteria. Secondary endpoints included the incidence of RP grade 3 or greater and changes in pulmonary function measured with the Common Terminology Criteria for Adverse Events version 3.0 scales, pulmonary function tests and community-acquired pneumonia questionnaires, obtained at baseline and 6 months after IMRT. Clinical follow-up was every 6 months for up to 5 years.
Median follow-up was 53.4 months (range, 0-82 months). Of 113 patients enrolled, 104 completed follow-up procedures. Coverage of the breast or chest wall and IMN was comprehensive (median 48.1 Gy and 48.9 Gy, respectively). The median volume of lung receiving a high dose (V20Gy) and a low dose (V5) was 29% and 100%, respectively. The overall rate of respiratory toxicities was 10.6% (11/104), including 1 grade 3 RP event (0.96%). No differences were found in pulmonary function test or community-acquired pneumonia scores after IMRT. The 5-year rates of locoregional recurrence-free, disease-free, and overall survival were 93.2%, 63.6%, and 80.3%, respectively.
Multibeam IMRT in patients with breast cancer receiving regional nodal irradiation was dosimetrically feasible, based on early treatment planning criteria. Despite the large volume of lung receiving low-dose RT, the incidence of grade 3 RP was remarkably low, justifying inverse-planned IMRT as a treatment modality for patients with high-risk breast cancer in whom conventional RT techniques prove inadequate.
多束强度调制放射治疗(IMRT)通过增加靶肿瘤组织的剂量覆盖范围,同时最大限度地减少接受高剂量 RT 的相邻器官的体积,从而提高治疗指数。其权衡是,更大体积的肺会受到低剂量 RT 的照射,这引发了对放射性肺炎(RP)风险的担忧。
在 2010 年 7 月至 2013 年 1 月期间,患有淋巴结阳性乳腺癌的患者接受了逆向计划的多束 IMRT,包括乳房或胸壁以及区域淋巴结,包括内乳淋巴结(IMN)。主要终点是剂量学治疗计划标准规定的可行性。次要终点包括 3 级或更高级别的 RP 发生率以及使用通用不良事件术语标准 3.0 量表、肺功能测试和社区获得性肺炎问卷测量的肺功能变化,在 IMRT 后 6 个月和基线时获得。临床随访每 6 个月进行一次,最长可达 5 年。
中位随访时间为 53.4 个月(范围,0-82 个月)。在 113 名入组患者中,有 104 名完成了随访程序。乳房或胸壁和 IMN 的覆盖范围全面(中位数分别为 48.1Gy 和 48.9Gy)。接受高剂量(V20Gy)和低剂量(V5)照射的肺的中位数体积分别为 29%和 100%。总体呼吸毒性发生率为 10.6%(11/104),包括 1 例 3 级 RP 事件(0.96%)。IMRT 后肺功能测试或社区获得性肺炎评分无差异。5 年局部区域无复发生存率、无病生存率和总生存率分别为 93.2%、63.6%和 80.3%。
根据早期治疗计划标准,在接受区域淋巴结照射的乳腺癌患者中,多束 IMRT 在剂量学上是可行的。尽管大量的肺接受低剂量 RT,但 3 级 RP 的发生率非常低,这证明了逆向计划 IMRT 是高危乳腺癌患者的一种治疗方式,对于那些常规 RT 技术不足的患者来说是合理的。